SI2600830T1 - Formulacija suhega praška, obsegajoča fosfodiesterazni inhibitor - Google Patents
Formulacija suhega praška, obsegajoča fosfodiesterazni inhibitor Download PDFInfo
- Publication number
- SI2600830T1 SI2600830T1 SI201131448T SI201131448T SI2600830T1 SI 2600830 T1 SI2600830 T1 SI 2600830T1 SI 201131448 T SI201131448 T SI 201131448T SI 201131448 T SI201131448 T SI 201131448T SI 2600830 T1 SI2600830 T1 SI 2600830T1
- Authority
- SI
- Slovenia
- Prior art keywords
- inhalable
- powder according
- dry powder
- inhalable powder
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (18)
- FORMULACIJA SUHEGA PRAŠKA, OBSEGAJOČA FOSFODIESTERAZNI INHIBITOR PATENTNI ZAHTEVKI1. Inhalabilna formulacija suhega praška, ki obsega mikronizirane delce spojine s splošno formulo (I) kot (-) enantiomer, kjer:n je 0 ali 1; Ri in R2 sta lahko enaka ali različna in sta izbrana iz skupine, ki jo sestavljajo: - linearen ali razvejen CrCe alkil, opcijsko substituiran z enim ali več atomi halogena; - OR3, kjer je R3 linearen ali razvejen Ci-C6 alkil, opcijsko substituiran z enim ali več atomi halogena ali C3-C7 cikloalkilnimi skupinami; in - HNSO2R4, kjer je R4 linearen ali razvejen C1-C4 alkil, opcijsko substituiran z enim ali več atomi halogena, kjer je vsaj eden od R1 in R2 HNSO2R4; in grobe delce nosilca, narejene iz fiziološko sprejemljive farmakološko inertne snovi z masnim premerom 150 do 400 mikronov; kjer se omenjena spojina daje v terapevtsko učinkovitem enkratnem odmerku, ki je med 300 pg in 2000 pg.
- 2. Inhalabilen prašek po zahtevku 1, kjer je enkratni odmerek med 300 pg in 600 M9·
- 3. Inhalabilen prašek po zahtevku 2, kjer je enkratni odmerek 400 pg ali 600 pg.
- 4. Inhalabilen prašek po katerem koli od zahtevkov 1 do 3, kjer je spojina s formulo (I) 1 -(3-ciklopropilmetoksi-4-difluorometoksi-fenil)-2-(3,5-dikloro-1 -oksi-piridin-4-il)-etil ester (-)-3-ciklopropilmetoksi-4-metansulfonilamino-benzojske kisline (C2).
- 5. Inhalabilen prašek po katerem koli od zahtevkov 1 do 4, kjer je fiziološko sprejemljiva farmakološko inertna snov kristalinični sladkor, izbran iz skupine, ki jo sestavljajo glukoza, arabinoza, maltoza, saharoza, dekstroza in laktoza ali polialkohol, izbran iz skupine, ki jo sestavljajo manitol, maltitol, laktitol in sorbitol.
- 6. Inhalabilen prašek po zahtevku 5, kjer je sladkor laktoza.
- 7. Inhalabilen prašek po zahtevku 6, kjer je sladkor α-laktoza monohidrat.
- 8. Inhalabilen prašek po katerem koli od zahtevkov 1 do 7, kjer imajo grobi delci nosilca masni premer, ki je med 212 in 355 mikroni.
- 9. Inhalabilen prašek po katerem koli od predhodnih zahtevkov, ki nadalje obsega eno ali več aditivnih snovi, izbranih iz skupine, ki jo sestavljajo aminokisline, v vodi topna površinsko aktivna sredstva, maziva in drsila.
- 10. Inhalabilen prašek po zahtevku 9, kjer je aditivna snov mazivo.
- 11. Inhalabilen prašek po zahtevku 10, kjer je aditivna snov magnezijev stearat.
- 12. Inhalabilen prašek po zahtevku 11, kjer je magnezijev stearat prisoten v količini, ki je med 0,01 in 2 mas. % glede na celotno maso formulacije.
- 13. Inhalabilen prašek po zahtevku 12, kjer je količina magnezijevega stearata med 0,02 in 1 % m/m.
- 14. Inhalabilen prašek po katerem koli od predhodnih zahtevkov, ki nadalje obsega na drobno razdeljene delce fiziološko sprejemljive farmakološko inertne snovi z MMD, ki je enak ali manjši kot 15 mikronov.
- 15. Inhalator za suh prašek, ki obsega inhalabilno formulacijo suhega praška po katerem koli od zahtevkov 1 do 14.
- 16. Inhalabilna formulacija suhega praška po katerem koli od zahtevkov 1 do 14, za uporabo za preprečevanje in/ali zdravljenje respiratorne bolezni.
- 17. Inhalabilna formulacija suhega praška po zahtevku 16, kjer je bolezen astma in kronična obstrukcijska pljučna bolezen (COPD).
- 18. Ovojnina, ki obsega inhalabilno formulacijo suhega praška po katerem koli od zahtevkov 1 do 14 in inhalator za suh prašek.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10171748 | 2010-08-03 | ||
| EP11741172.8A EP2600830B1 (en) | 2010-08-03 | 2011-07-27 | Dry powder formulation comprising a phosphodiesterase inhibitor |
| PCT/EP2011/062872 WO2012016889A2 (en) | 2010-08-03 | 2011-07-27 | Dry powder formulation comprising a phosphodiesterase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2600830T1 true SI2600830T1 (sl) | 2018-05-31 |
Family
ID=43262631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201131448T SI2600830T1 (sl) | 2010-08-03 | 2011-07-27 | Formulacija suhega praška, obsegajoča fosfodiesterazni inhibitor |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US9132121B2 (sl) |
| EP (2) | EP2600830B1 (sl) |
| JP (1) | JP6004233B2 (sl) |
| KR (1) | KR101805958B1 (sl) |
| CN (2) | CN103052379A (sl) |
| AR (1) | AR082443A1 (sl) |
| AU (1) | AU2011287711B2 (sl) |
| BR (1) | BR112013002506A2 (sl) |
| CA (1) | CA2807256C (sl) |
| CL (1) | CL2013000293A1 (sl) |
| CO (1) | CO6690744A2 (sl) |
| CY (1) | CY1120605T1 (sl) |
| DK (1) | DK2600830T3 (sl) |
| EA (2) | EA027692B1 (sl) |
| ES (1) | ES2664175T3 (sl) |
| GE (1) | GEP20156343B (sl) |
| HR (1) | HRP20180717T1 (sl) |
| HU (1) | HUE037620T2 (sl) |
| IL (1) | IL224517B (sl) |
| LT (1) | LT2600830T (sl) |
| MA (1) | MA34449B1 (sl) |
| ME (1) | ME03022B (sl) |
| MX (1) | MX346424B (sl) |
| MY (1) | MY179703A (sl) |
| NO (1) | NO2600830T3 (sl) |
| NZ (1) | NZ606548A (sl) |
| PE (2) | PE20171256A1 (sl) |
| PL (1) | PL2600830T3 (sl) |
| PT (1) | PT2600830T (sl) |
| RS (1) | RS57061B1 (sl) |
| SG (1) | SG187258A1 (sl) |
| SI (1) | SI2600830T1 (sl) |
| TR (1) | TR201807012T4 (sl) |
| UA (1) | UA112296C2 (sl) |
| WO (1) | WO2012016889A2 (sl) |
| ZA (1) | ZA201300870B (sl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
| WO2008095136A2 (en) | 2007-01-31 | 2008-08-07 | Henkin Robert I | Methods for detection of biological substances |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| US8580801B2 (en) | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
| EP2216327A1 (en) | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| US20130005716A1 (en) | 2011-06-06 | 2013-01-03 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| JP6434416B2 (ja) | 2012-11-08 | 2018-12-05 | ライゼン・ファーマシューティカルズ・エスアー | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 |
| WO2014143453A1 (en) * | 2013-03-15 | 2014-09-18 | Henkin Robert I | Phosphodiesterase inhibitor treatment |
| US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
| SI3587400T1 (sl) | 2013-10-22 | 2024-05-31 | Chiesi Farmaceutici S.P.A. | Postopek za pripravo zaviralca pde4 |
| EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| EP3108245B1 (en) | 2014-02-18 | 2020-07-22 | Robert I. Henkin | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
| EP3166641B1 (en) | 2014-07-09 | 2018-09-12 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for the preparation of formulations for inhalation |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| US10583085B2 (en) * | 2017-05-17 | 2020-03-10 | Chiesi Farmaceutici S.P.A. | Carrier particles for dry powder formulations for inhalation |
| KR101859752B1 (ko) * | 2017-09-13 | 2018-05-21 | 심원 | 조립식 열 저장 운반장치 |
| KR101859750B1 (ko) * | 2017-09-13 | 2018-05-21 | 제일에스엠피(주) | 고정식 열 저장 운반장치 |
| WO2023117985A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
| WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
| WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
| WO2024062007A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| WO2024062005A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
| WO2024062006A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19841248A1 (de) | 1997-09-12 | 1999-04-29 | Fraunhofer Ges Forschung | Demonstrationseinrichtung in Form eines Lebewesens |
| EP1015895B1 (de) | 1997-09-16 | 2001-07-11 | Trench Switzerland AG | Spannungsteiler |
| ATE363892T1 (de) | 1999-03-05 | 2007-06-15 | Chiesi Farma Spa | Verbesserte pulverformulierungen zur inhalation |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| EP1913939B1 (en) | 2000-06-27 | 2017-05-31 | Vectura Limited | Formulations for use in inhaler devices |
| US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
| ES2359576T5 (es) | 2002-07-31 | 2020-03-03 | Chiesi Farm Spa | Inhalador de polvo |
| DE10255387A1 (de) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Tiotropium-haltige Pulverformulierung für die Inhalation |
| GB0326632D0 (en) * | 2003-11-14 | 2003-12-17 | Jagotec Ag | Dry powder formulations |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| WO2006131452A1 (en) * | 2005-06-06 | 2006-12-14 | F. Hoffmann-La Roche Ag | SULFONAMIDE DERIVATIVES USEFUL AS LIVER CARNITINE PALMITOYL TRANSFERASE (L-CPTl) INHIBITORS |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
| EP2070913A1 (en) * | 2007-12-14 | 2009-06-17 | CHIESI FARMACEUTICI S.p.A. | Ester derivatives as phosphodiesterase inhibitors |
| EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| KR101803121B1 (ko) | 2010-08-03 | 2017-11-29 | 키에시 파르마슈티시 엣스. 피. 에이. | 포스포디에스테라제 억제제를 포함하는 약학적 제제 |
| US20130005716A1 (en) | 2011-06-06 | 2013-01-03 | Chiesi Farmaceutici S.P.A. | Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors |
| SI3587400T1 (sl) | 2013-10-22 | 2024-05-31 | Chiesi Farmaceutici S.P.A. | Postopek za pripravo zaviralca pde4 |
-
2011
- 2011-07-27 EP EP11741172.8A patent/EP2600830B1/en active Active
- 2011-07-27 GE GEAP201112988A patent/GEP20156343B/en unknown
- 2011-07-27 NZ NZ606548A patent/NZ606548A/en unknown
- 2011-07-27 CA CA2807256A patent/CA2807256C/en active Active
- 2011-07-27 CN CN2011800382903A patent/CN103052379A/zh active Pending
- 2011-07-27 TR TR2018/07012T patent/TR201807012T4/tr unknown
- 2011-07-27 AU AU2011287711A patent/AU2011287711B2/en active Active
- 2011-07-27 BR BR112013002506A patent/BR112013002506A2/pt not_active Application Discontinuation
- 2011-07-27 ME MEP-2018-101A patent/ME03022B/me unknown
- 2011-07-27 MY MYPI2013000339A patent/MY179703A/en unknown
- 2011-07-27 WO PCT/EP2011/062872 patent/WO2012016889A2/en active Application Filing
- 2011-07-27 EA EA201690541A patent/EA027692B1/ru unknown
- 2011-07-27 EP EP17176635.5A patent/EP3246016A1/en active Pending
- 2011-07-27 JP JP2013522202A patent/JP6004233B2/ja active Active
- 2011-07-27 KR KR1020137002872A patent/KR101805958B1/ko active IP Right Grant
- 2011-07-27 MX MX2013001172A patent/MX346424B/es active IP Right Grant
- 2011-07-27 SG SG2013008107A patent/SG187258A1/en unknown
- 2011-07-27 RS RS20180394A patent/RS57061B1/sr unknown
- 2011-07-27 MA MA35635A patent/MA34449B1/fr unknown
- 2011-07-27 EA EA201390049A patent/EA024922B1/ru unknown
- 2011-07-27 HU HUE11741172A patent/HUE037620T2/hu unknown
- 2011-07-27 PE PE2017001245A patent/PE20171256A1/es unknown
- 2011-07-27 UA UAA201302607A patent/UA112296C2/uk unknown
- 2011-07-27 SI SI201131448T patent/SI2600830T1/sl unknown
- 2011-07-27 CN CN201710259305.8A patent/CN106890165A/zh active Pending
- 2011-07-27 DK DK11741172.8T patent/DK2600830T3/en active
- 2011-07-27 ES ES11741172.8T patent/ES2664175T3/es active Active
- 2011-07-27 NO NO11741172A patent/NO2600830T3/no unknown
- 2011-07-27 PL PL11741172T patent/PL2600830T3/pl unknown
- 2011-07-27 PT PT117411728T patent/PT2600830T/pt unknown
- 2011-07-27 LT LTEP11741172.8T patent/LT2600830T/lt unknown
- 2011-07-27 PE PE2013000155A patent/PE20130601A1/es active IP Right Grant
- 2011-08-02 US US13/195,885 patent/US9132121B2/en active Active
- 2011-08-02 AR ARP110102782 patent/AR082443A1/es not_active Application Discontinuation
-
2013
- 2013-01-30 CL CL2013000293A patent/CL2013000293A1/es unknown
- 2013-01-31 IL IL224517A patent/IL224517B/en active IP Right Grant
- 2013-02-01 ZA ZA2013/00870A patent/ZA201300870B/en unknown
- 2013-02-01 CO CO13019325A patent/CO6690744A2/es unknown
-
2015
- 2015-08-07 US US14/820,939 patent/US9308200B2/en active Active
-
2018
- 2018-03-09 CY CY181100288T patent/CY1120605T1/el unknown
- 2018-05-09 HR HRP20180717TT patent/HRP20180717T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2600830T1 (sl) | Formulacija suhega praška, obsegajoča fosfodiesterazni inhibitor | |
| RU2013142268A (ru) | Фармацевтическая композиция | |
| RU2013119938A (ru) | Фармацевтическая композиция | |
| JP2013526580A5 (sl) | ||
| HRP20191686T1 (hr) | Mikronizirane čestice aktivnih tvari za praškaste formulacije za inhalaciju u niskim dozama | |
| WO2012035559A3 (en) | Sustained release pharmaceutical compositions comprising pregabalin | |
| KR20130111967A (ko) | 항무스카린성 약물을 포함하는 건조 분말 제제 | |
| EP2621494A1 (en) | Use of magnesium stearate in dry powder formulations for inhalation | |
| RU2013106866A (ru) | Фармацевтические композиции | |
| WO2009090008A1 (en) | Dry powder formulation comprising an anticholinergic drug | |
| JP2018530578A (ja) | 組み合せ抗細菌組成物および短期抗細菌レジメン | |
| KR20170003601A (ko) | Ｃｏｐｄ의 치료를 위한 티오트로피움 브로마이드, 포르모테롤 및 부데소니드의 조합 | |
| CA2684539A1 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| JP2018527291A (ja) | 駆虫薬の大環状ラクトンを含むミクロスフェア | |
| JP2013500270A (ja) | 抗結核剤としてのスペクチナミド類 | |
| JP2008088189A5 (sl) | ||
| WO2021091801A1 (en) | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods of treatment comprising them | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| KR20160127712A (ko) | 다제내성 결핵 치료를 위한 흡입 에어로졸 면역화학요법 | |
| JP2023550407A (ja) | 肺高血圧向けの吸入式イマチニブ | |
| JP2022512208A (ja) | ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法 | |
| JP2009538822A5 (sl) | ||
| RU2014144145A (ru) | Фармацевтическая композиция, содержащая арформотерол и флутиказона фуроат | |
| US20060286040A1 (en) | Medicament compositions comprising a heterocyclic compound and an anticholinergic |